Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
TRIB's Cash to Debt is ranked higher than
91% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. TRIB: No Debt )
TRIB' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: No Debt

Equity to Asset 0.82
TRIB's Equity to Asset is ranked higher than
89% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. TRIB: 0.82 )
TRIB' s 10-Year Equity to Asset Range
Min: 0.29   Max: 0.88
Current: 0.82

0.29
0.88
Interest Coverage 176.37
TRIB's Interest Coverage is ranked higher than
72% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.48 vs. TRIB: 176.37 )
TRIB' s 10-Year Interest Coverage Range
Min: 0.73   Max: 9999.99
Current: 176.37

0.73
9999.99
F-Score: 6
Z-Score: 7.64
M-Score: -2.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 10.02
TRIB's Operating margin (%) is ranked higher than
85% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. TRIB: 10.02 )
TRIB' s 10-Year Operating margin (%) Range
Min: -56.78   Max: 21.86
Current: 10.02

-56.78
21.86
Net-margin (%) 17.10
TRIB's Net-margin (%) is ranked higher than
95% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. TRIB: 17.10 )
TRIB' s 10-Year Net-margin (%) Range
Min: -63.46   Max: 67.4
Current: 17.1

-63.46
67.4
ROE (%) 9.45
TRIB's ROE (%) is ranked higher than
83% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. TRIB: 9.45 )
TRIB' s 10-Year ROE (%) Range
Min: -76.72   Max: 54.77
Current: 9.45

-76.72
54.77
ROA (%) 7.68
TRIB's ROA (%) is ranked higher than
89% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. TRIB: 7.68 )
TRIB' s 10-Year ROA (%) Range
Min: -45.03   Max: 41.2
Current: 7.68

-45.03
41.2
ROC (Joel Greenblatt) (%) 20.30
TRIB's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. TRIB: 20.30 )
TRIB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -400   Max: 49.19
Current: 20.3

-400
49.19
Revenue Growth (3Y)(%) -2.80
TRIB's Revenue Growth (3Y)(%) is ranked higher than
66% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. TRIB: -2.80 )
TRIB' s 10-Year Revenue Growth (3Y)(%) Range
Min: -30.9   Max: 108.2
Current: -2.8

-30.9
108.2
EBITDA Growth (3Y)(%) -42.20
TRIB's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. TRIB: -42.20 )
TRIB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -45.8   Max: 125.1
Current: -42.2

-45.8
125.1
EPS Growth (3Y)(%) -47.60
TRIB's EPS Growth (3Y)(%) is ranked higher than
54% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. TRIB: -47.60 )
TRIB' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.9   Max: 75.6
Current: -47.6

-52.9
75.6
» TRIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

TRIB Guru Trades in Q4 2013

Jim Simons 485,221 sh (-4.52%)
Chuck Royce 322,000 sh (-5.85%)
» More
Q1 2014

TRIB Guru Trades in Q1 2014

Jim Simons 450,272 sh (-7.2%)
Chuck Royce 278,924 sh (-13.38%)
» More
Q2 2014

TRIB Guru Trades in Q2 2014

Jim Simons 451,050 sh (+0.17%)
Chuck Royce 265,000 sh (-4.99%)
» More
Q3 2014

TRIB Guru Trades in Q3 2014

Chuck Royce 265,000 sh (unchged)
Jim Simons 430,150 sh (-4.63%)
» More
» Details

Insider Trades

Latest Guru Trades with TRIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Keeley 2011-09-30 Sold Out 0.0026%$9.25 - $10.83 $ 17.4972%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 9.60
TRIB's P/E(ttm) is ranked higher than
99% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TRIB: 9.60 )
TRIB' s 10-Year P/E(ttm) Range
Min: 2.08   Max: 47.8
Current: 9.6

2.08
47.8
P/B 2.13
TRIB's P/B is ranked higher than
89% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.37 vs. TRIB: 2.13 )
TRIB' s 10-Year P/B Range
Min: 0.23   Max: 3.49
Current: 2.13

0.23
3.49
P/S 1.63
TRIB's P/S is ranked higher than
86% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.06 vs. TRIB: 1.63 )
TRIB' s 10-Year P/S Range
Min: 0.16   Max: 5.57
Current: 1.63

0.16
5.57
EV-to-EBIT 37.99
TRIB's EV-to-EBIT is ranked higher than
80% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TRIB: 37.99 )
TRIB' s 10-Year EV-to-EBIT Range
Min: -1.7   Max: 149.5
Current: 37.99

-1.7
149.5
Shiller P/E 27.62
TRIB's Shiller P/E is ranked higher than
93% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TRIB: 27.62 )
TRIB' s 10-Year Shiller P/E Range
Min: 2.05   Max: 1698
Current: 27.62

2.05
1698
Current Ratio 4.31
TRIB's Current Ratio is ranked higher than
81% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. TRIB: 4.31 )
TRIB' s 10-Year Current Ratio Range
Min: 1   Max: 9.17
Current: 4.31

1
9.17
Quick Ratio 2.17
TRIB's Quick Ratio is ranked higher than
71% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. TRIB: 2.17 )
TRIB' s 10-Year Quick Ratio Range
Min: 0.44   Max: 7.6
Current: 2.17

0.44
7.6

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.26
TRIB's Dividend Yield is ranked higher than
92% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.31 vs. TRIB: 1.26 )
TRIB' s 10-Year Dividend Yield Range
Min: 0.72   Max: 1.35
Current: 1.26

0.72
1.35
Dividend Payout 0.51
TRIB's Dividend Payout is ranked higher than
87% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TRIB: 0.51 )
TRIB' s 10-Year Dividend Payout Range
Min: 0.3   Max: 0.78
Current: 0.51

0.3
0.78
Yield on cost (5-Year) 1.20
TRIB's Yield on cost (5-Year) is ranked higher than
81% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. TRIB: 1.20 )
TRIB' s 10-Year Yield on cost (5-Year) Range
Min: 0.72   Max: 1.35
Current: 1.2

0.72
1.35
Share Buyback Rate -3.40
TRIB's Share Buyback Rate is ranked higher than
76% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.60 vs. TRIB: -3.40 )
TRIB' s 10-Year Share Buyback Rate Range
Min: 26.2   Max: -79.2
Current: -3.4

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 159.00
TRIB's Price/Net Current Asset Value is ranked higher than
77% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TRIB: 159.00 )
TRIB' s 10-Year Price/Net Current Asset Value Range
Min: 1.43   Max: 296
Current: 159

1.43
296
Price/Tangible Book 7.81
TRIB's Price/Tangible Book is ranked higher than
71% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.74 vs. TRIB: 7.81 )
TRIB' s 10-Year Price/Tangible Book Range
Min: 0.45   Max: 225
Current: 7.81

0.45
225
Price/DCF (Projected) 3.04
TRIB's Price/DCF (Projected) is ranked higher than
85% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TRIB: 3.04 )
TRIB' s 10-Year Price/DCF (Projected) Range
Min: 0.24   Max: 78.35
Current: 3.04

0.24
78.35
Price/Median PS Value 1.21
TRIB's Price/Median PS Value is ranked higher than
75% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. TRIB: 1.21 )
TRIB' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 5.56
Current: 1.21

0.17
5.56
Price/Graham Number 2.85
TRIB's Price/Graham Number is ranked higher than
87% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TRIB: 2.85 )
TRIB' s 10-Year Price/Graham Number Range
Min: 0.27   Max: 11.25
Current: 2.85

0.27
11.25
Earnings Yield (Greenblatt) 2.60
TRIB's Earnings Yield (Greenblatt) is ranked higher than
79% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. TRIB: 2.60 )
TRIB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 96.3
Current: 2.6

0.7
96.3
Forward Rate of Return (Yacktman) 0.91
TRIB's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.35 vs. TRIB: 0.91 )
TRIB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -30.6   Max: 17.6
Current: 0.91

-30.6
17.6

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:TRBA.Germany,
Trinity Biotech PLC was incorporated as a public limited company, registered in Ireland in January 1992. The Company commenced operations in 1992 and, in October 1992, completed an initial public offering of its securities in the US. The Company develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. It is also a significant provider of raw materials to the life sciences industry. It sells over 400 products to customers in 110 countries through its own sales force and a network of international distributors and strategic partners. The primary market for Trinity Biotech's tests remains the USA. The Company develops, acquires, manufactures and markets clinical in-vitro diagnostic products. It supplies the clinical laboratory segment of the of the in-vitro diagnostic market. It also sells raw materials to the life sciences industry. Its Point-of-Care product is Unigold(tm), which tests for the presence of HIV antibodies. It sells its product through its own direct sales-force in four countries: the United States, Germany, France and the United Kingdom. Its compeitors are bbott Diagnostics, Alere Inc., Arkray, Bio-Rad, Diasorin Inc., Euroimmun, Johnson & Johnson, OraSure Technologies Inc., Phadia, Roche Diagnostics, Siemens (from the combined acquisitions of Bayer, Dade-Behring and DPC), Thermo Fisher, Tosoh and Werfen. The preclinical and clinical testing, manufacture, labelling, distribution, and promotion of Trinity Biotech's products are subject to extensive and rigorous government regulation in the United States and in other countries in which its products are sought to be marketed.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK